AZD4635 + durvalumab + cabazitaxel

This is a **multi-drug combination regimen** being explored for the treatment of metastatic castration-resistant prostate cancer (mCRPC)[5][1][3]. - **AZD4635** is an orally bioavailable small molecule antagonist of the adenosine A2A receptor; it inhibits adenosine binding, modulating the tumor microenvironment to enhance immune-mediated antitumor responses[1]. - **Durvalumab** is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80, thereby facilitating T-cell activation and tumor cell elimination[1]. - **Cabazitaxel** is a microtubule inhibitor (chemotherapy drug) that prevents cell division by stabilizing microtubules and impairing mitotic function, mainly used in advanced prostate cancer[4][2][6][8]. The combination aims to leverage **immune checkpoint blockade** (via durvalumab), **adenosine signaling inhibition** (via AZD4635), and **cytotoxicity** (via cabazitaxel) to potentiate antitumor activity.

Other names

AZD4635 + durvalumab + cabazitaxel